
|Articles|October 26, 2021
Daily Medication Pearl: Harvoni (Ledipasvir and Sofosbuvir)
Author(s)Saro Arakelians, PharmD
Harvoni is a fixed-dose combination indicated for the treatment of chronic hepatitis C virus in adults and pediatric patients 3 years of age and older.
Advertisement
Medication Pearl of the Day:Harvoni (Ledipasvir and Sofosbuvir)
Indication: Harvoni is a fixed-dose combination of ledipasvir and sofosbuvir, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older.
Insight:
- Dosing: Recommended dosage in adults 1 tablet (90 mg of ledipasvir and 400 mg of sofosbuvir) taken orally once daily with or without food.
- Dosage form: Tablets 90 mg of ledipasvir and 400 mg of sofosbuvir; 45 mg of ledipasvir and 200 mg of sofosbuvir.
- Adverse events (AEs): The most common AEs (incidence greater than or equal to 10%, all grades) observed from treatment with Harvoni were fatigue, headache, and asthenia.
- Mechanism of action: Harvoni is a fixed-dose combination of an HCV NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor.
- Manufacturer: Gilead
Sources:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
3
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
4
Could VER-01 Redefine the Role of Cannabis in Chronic Pain Care?
5





































































































